cranial nerve palsy: Injury to any of the cranial nerves or their nuclei in the brain resulting in muscle weakness.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
96 |
4. Check minimum number of eventsNone |
96 |
5. Include endpointsNone |
96 |
6. Filter based on genotype QC (FinnGen only) |
93 |
Control definitions (FinnGen only)
- Control exclude
- G6_NERPLEX
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Other cranial nerve disorders in other disorders
based on the number of shared cases.
Similar with more cases:
- Nerve, nerve root and plexus disorders
- Neurological diseases
- Neurological diseases, wide definition
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 548 | 312 | 234 |
| Only index persons | 506 | 292 | 214 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 50.47 | 51.53 | 48.97 |
| Only index persons | 48.97 | 49.40 | 48.38 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 93 | 55 | 38 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | 47.71 | 46.13 | 50.00 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 96
- Matched controls
- 960
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G53.2*D86.8
ICD-10 Finland
Multiple cranial nerve palsies in sarcoidosis
+∞
76.6
63
*
D86.8
ICD-10 Finland
Sarcoidosis of other and combined sites
187.3
58.0
56
7
D86.9
ICD-10 Finland
Sarcoidosis, unspecified
128.9
38.3
39
5
132
Kela drug reimbursment
Sarcoidosis
172.5
34.3
34
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
14.4
33.2
37
40
D86.0
ICD-10 Finland
Sarcoidosis of lung
98.8
31.3
33
5
TAB00
NOMESCO Finland
Lumbar puncture
14.8
29.6
31
30
G51.0
ICD-10 Finland
Bell palsy
+∞
26.2
24
*
G53.2
ICD-10 Finland
Multiple cranial nerve palsies in sarcoidosis
+∞
19.4
18
*
D86.2
ICD-10 Finland
Sarcoidosis of lung with sarcoidosis of lymph nodes
62.3
17.8
20
*
M05BA04
ATC
alendronic acid; oral
9.1
17.0
24
34
H02AB06
ATC
prednisolone; systemic
6.3
15.7
72
309
Z01.0
ICD-10 Finland
Examination of eyes and vision
5.4
13.9
38
104
L04AX01
ATC
azathioprine; systemic
16.4
13.8
22
17
D86.1
ICD-10 Finland
Sarcoidosis of lymph nodes
74.3
11.9
13
*
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
15.5
11.8
19
15
H04.10
ICD-10 Finland
Dry eye syndrome
5.2
10.8
27
67
GD1AA
NOMESCO Finland
Thorax X-ray examination
4.1
10.3
62
295
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
3.9
10.1
51
215
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
5.0
9.9
26
67
G53.1
ICD-10 Finland
Multiple cranial nerve palsies in infectious and parasitic diseases classified elsewhere
+∞
9.5
9
*
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
9.6
9.4
19
24
D86.3
ICD-10 Finland
Sarcoidosis of skin
98.3
8.6
9
*
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
36.8
8.3
10
*
TPH04
NOMESCO Finland
Cathetrisation of vein
3.8
8.3
34
122
H02AB07
ATC
prednisone; oral
4.4
8.2
24
67
N03AX12
ATC
[U] gabapentin; oral
4.0
7.7
27
86
XCK00
NOMESCO Finland
Perimetry
7.7
7.5
17
26
M14.8*D86.8
ICD-10 Finland
Arthropathy in sarcoidosis
+∞
7.4
7
*
R20.2
ICD-10 Finland
Paraesthesia of skin
5.1
7.3
17
39
A02BC01
ATC
omeprazole; systemic
3.3
7.1
37
153
G56.0
ICD-10 Finland
Carpal tunnel syndrome
12.3
7.0
12
11
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
4.7
6.7
17
42
R42
ICD-10 Finland
Dizziness and giddiness
3.3
6.7
34
138
L04AX03
ATC
methotrexate; systemic
4.3
6.6
19
52
C03DA01
ATC
spironolactone; oral
4.2
6.6
20
57
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
8.0
6.5
14
20
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
6.6
6.5
16
28
A02BC02
ATC
pantoprazole; systemic
3.5
6.2
76
500
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
4.6
6.2
16
40
L30.9
ICD-10 Finland
Dermatitis, unspecified
3.2
6.2
31
124
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
13
6
24.70
9.64
1.2
1.0
—
—
—
0
0
12
6
22.54
8.71
1.0
1.0
—
—
—
0
0
63
335
3.56
8.21
10.1
6.6
1.23
1.21
mmol/l
1.02
50
291
11
9
13.60
6.77
1.0
1.1
—
—
—
0
0
22
73
3.61
5.83
3.3
1.7
333.82
384.03
nmol/l
0.67
22
66
10
10
10.99
5.68
1.0
1.1
—
—
—
0
0
69
448
2.92
5.38
13.8
10.5
3.79
4.08
e9/l
0.59
61
395
12
23
5.80
4.63
2.0
1.3
—
0.12
—
0
6
7
6
12.44
4.34
1.1
1.0
—
—
—
0
0
46
274
2.30
3.88
4.3
3.6
17.63
33.34
ng/l
1.47
36
186
13
35
4.13
3.77
2.1
2.1
0.71
1.05
mmol/l
—
8
29
40
228
2.29
3.71
1.9
2.2
122.40
174.00
u/l
1.20
35
214
38
232
2.06
2.83
4.4
3.5
4.69
8.53
mg/mmol
0.48
28
152
20
95
2.40
2.73
2.9
2.3
2.34
2.44
g/l
0.35
20
85
35
210
2.05
2.71
4.2
2.9
787.73
1532.14
ng/l
0.99
28
180
17
77
2.47
2.55
2.2
1.7
—
—
—
0
0
17
80
2.37
2.36
2.3
1.7
—
—
—
0
0
48
334
1.87
2.35
15.8
13.2
1.41
1.23
inr
0.34
11
103
38
254
1.82
2.06
6.0
2.8
—
—
—
0
0
6
16
3.93
1.96
3.2
1.2
22.75
24.55
mmol/l
—
6
16
5
11
4.73
1.96
1.8
1.2
—
—
—
0
0
7
23
3.20
1.83
2.0
1.7
—
—
—
0
0
5
13
3.99
1.73
1.6
1.8
—
—
—
0
0
5
13
3.99
1.73
1.6
1.8
—
—
—
0
0
23
138
1.88
1.72
1.1
1.2
1.41
4.26
u/ml
—
10
58
22
131
1.88
1.68
6.1
3.0
21.88
140.03
ng/l
1.30
16
97
51
397
1.61
1.46
6.5
4.6
0.00
0.00
estimate
—
8
75
51
399
1.59
1.42
5.0
3.3
0.00
0.00
estimate
—
9
80
18
106
1.86
1.42
2.2
1.8
—
—
—
0
0
51
403
1.57
1.34
5.0
3.3
0.00
0.00
estimate
—
9
73
5
18
2.87
1.30
3.2
2.5
—
—
—
0
0
21
135
1.71
1.25
1.8
1.5
—
—
—
0
0
19
119
1.74
1.23
4.1
2.2
1.92
1.27
e6/l
0.27
13
67
5
20
2.58
1.16
4.0
1.5
92.40
95.10
%
—
5
20
43
335
1.51
1.16
2.5
2.3
—
—
—
0
0
7
30
2.44
1.15
1.0
1.1
—
—
—
0
0
22
147
1.64
1.14
1.1
1.2
11.50
35.90
iu/ml
—
5
51
7
31
2.35
1.13
1.9
2.0
—
—
—
0
0
38
290
1.51
1.12
2.1
1.8
93.97
92.99
pmol/l
0.05
24
147
17
106
1.73
1.12
7.7
2.4
1.63
3.34
e6/l
0.71
11
54
42
328
1.50
1.11
4.5
2.6
159.26
109.83
ug/l
0.68
42
303
87
803
1.89
1.11
22.0
12.3
14.76
23.11
mg/l
2.53
77
613
5
21
2.45
1.10
4.4
2.2
2.86
4.10
g/l
—
5
21
9
45
2.10
1.08
1.8
2.4
1.58
1.31
%
—
9
45
10
54
1.95
1.01
2.1
3.4
128.20
130.06
g/l
—
10
54
14
87
1.71
0.94
4.1
6.7
105.50
104.28
mmol/l
0.47
14
87
23
167
1.50
0.84
1.9
1.9
—
—
—
0
0
25
185
1.48
0.83
2.1
1.5
7.97
1.10
mg/l
0.42
19
150
6
34
1.81
0.77
2.2
2.0
—
—
—
0
0
59
515
1.38
0.76
3.8
3.1
—
—
—
0
0
7
41
1.76
0.71
1.1
1.2
—
—
—
0
0
22
166
1.42
0.66
1.3
1.2
0.40
2.21
u/ml
—
7
49
5
29
1.76
0.64
11.2
1.3
—
—
—
0
0
38
319
1.32
0.60
5.0
3.4
—
—
—
0
0
0
23
0.00
0.59
0.0
2.2
—
—
—
0
0
6
40
1.53
0.52
1.2
1.4
—
—
—
0
0
7
45
1.60
0.50
3.9
3.0
59.13
47.82
%
—
7
45
16
206
0.73
0.48
2.1
3.8
23.25
21.89
%
—
6
91
5
35
1.45
0.40
2.6
1.4
—
—
—
0
0
73
762
0.82
0.28
19.3
11.4
83.35
82.08
ml/min/173m2
0.20
67
634
11
137
0.78
0.26
1.5
2.3
2.44
2.44
mmol/l
0.00
11
123
25
220
1.18
0.24
5.5
3.4
0.00
0.00
estimate
—
9
73
0
11
0.00
0.21
0.0
1.2
—
2.20
—
0
5
0
11
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
213.28
—
0
10
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.6
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.5
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
89
898
0.88
0.18
32.5
18.5
40.44
40.76
%
0.19
81
857
9
82
1.11
0.15
1.8
2.2
—
—
—
0
0
11
96
1.16
0.11
8.5
8.6
—
—
—
0
0
80
788
1.09
0.06
4.5
3.9
1.52
1.32
mmol/l
1.17
75
737
77
758
1.08
0.06
8.4
5.2
41.67
39.43
mmol/mol
1.20
72
716
11
113
0.97
0.00
1.4
2.0
1.15
1.44
%
0.98
11
103
14
137
1.03
0.00
1.6
1.4
—
—
—
0
0
79
787
1.02
0.00
4.8
4.3
5.96
5.88
mmol/l
0.19
73
726
86
859
1.01
0.00
25.1
14.4
77.24
76.84
umol/l
0.06
86
859
0
6
0.00
-0.00
0.0
1.0
—
1573.50
—
0
6
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
3.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
4.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
97.38
—
0
8
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.7
—
—
—
0
0
7
72
0.97
-0.00
3.1
3.2
—
—
—
0
0
7
75
0.93
-0.00
1.6
2.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint G6_CRAINOTH and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_CRAINOTH | 2.04 [1.48, 2.81] | < 0.001 |
| Birth year | 0.993 [0.98, 1.0] | 0.114 |
During the follow-up period (1.1.1998 — 31.12.2019), 57 out of 292 females with G6_CRAINOTH died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_CRAINOTH | 1.899 [1.36, 2.64] | < 0.001 |
| Birth year | 0.989 [0.98, 1.0] | 0.037 |
During the follow-up period (1.1.1998 — 31.12.2019), 54 out of 223 males with G6_CRAINOTH died.
Mortality risk
Mortality risk for people of age
years, who have G6_CRAINOTH.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.163% | 0.463% |
| 5 | 1.165% | 2.375% |
| 10 | 2.897% | 6.245% |
| 15 | 5.219% | 11.758% |
| 20 | 9.075% | 18.899% |
Relationships between endpoints
↥Index endpoint: G6_CRAINOTH – Other cranial nerve disorders in other disorders
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data